Medifast, Inc. - MED STOCK NEWS

Medifast (NYSE: MED) released survey findings indicating that 70% of U.S. adults prioritize health, yet 50% struggle to do so, mainly due to lack of time and support. Only 28% of those on a traditional diet maintain it long-term, while 79% revert to previous habits. The survey also revealed that 67% believe more support would aid in reaching health goals. The COVID-19 pandemic has altered health priorities for 61% of respondents, underscoring the demand for holistic health solutions.

Medifast, Inc. (NYSE: MED) declared a $1.64 quarterly cash dividend for stockholders, payable on August 8, 2022, to those on record by June 28, 2022. The company is recognized as a leader in the weight management industry, impacting over 2 million lives with its OPTAVIA® program. The decision to pay future dividends will depend on the Board's discretion, considering relevant factors. Medifast aims to maintain quarterly dividend payments, signaling confidence in its financial stability and commitment to its shareholders.

Medifast, Inc. (NYSE: MED) announced that CEO Dan Chard and CFO Jim Maloney will engage with investors at the Jefferies Consumer Conference on June 20-22, 2022, in Nantucket, MA. A webcast of the session will be available on June 20, 2022, at 8:00am ET, accessible through Medifast's investor relations website. The company, known for its health and wellness community, continues to lead the U.S. weight management industry, serving over 2 million people through its OPTAVIA platform.

Medifast (NYSE: MED) announced a $100 million accelerated share repurchase (ASR) program with JPMorgan Chase to buy back approximately 600,000 shares, representing 5% of its outstanding stock. This move aims to enhance shareholder value and reflects the company's confidence in its growth strategy. Medifast plans to use available cash and borrowings for the ASR, with a remaining 1.4 million shares authorized for repurchase. The final settlement of the ASR will occur in Q3 2022, as the company continues to generate strong cash flow and invests in technology and product innovation.

Medifast has inaugurated the Medifast Product Innovation Center in Baltimore on May 10, 2022, to accelerate innovation and support its rapid growth in the $230 billion health and wellness market. The facility includes advanced office, lab, and pilot plant spaces, aimed at enhancing R&D, packaging engineering, and quality assurance. CEO Dan Chard highlighted that the company's revenue has doubled twice in five years, emphasizing the center's role in developing scientifically-backed products for its OPTAVIA program and expanding into new health segments.

Medifast, Inc. (NYSE: MED) reported a remarkable 22.6% increase in revenue to $417.6 million for Q1 2022, driven by a 21.7% rise in active OPTAVIA Coaches to 63,900. Net income grew 1.7% to $41.8 million, with earnings per share (EPS) at $3.59, a 3.8% increase. The company raised its annual revenue guidance to between $1.78 billion and $1.84 billion and adjusted full-year EPS expectations to $14.60 to $16.05. Despite growing expenses and lower gross profit margin, Medifast’s strong balance sheet and operational metrics indicate robust business health.

Medifast, Inc. (NYSE: MED) will announce its financial results for Q1 ended March 31, 2022, on May 2, 2022, after market close. A conference call with CEO Dan Chard and CFO Jim Maloney will follow at 4:30 p.m. ET, accessible via Medifast's investor relations website. Interested parties can also join via telephone at (855) 560-2579. The playback of the call will be available from May 2 through May 9, 2022. Medifast emphasizes its commitment to health and wellness through its OPTA VIA community, which has positively impacted over 2 million lives.

Medifast has declared a $1.64 quarterly cash dividend for its shareholders, payable on May 9, 2022. This dividend will be distributed to stockholders recorded as of the close of business on March 29, 2022. The company emphasizes its intention to maintain a quarterly dividend program, subject to the Board of Directors' discretion and evaluation based on relevant factors.

Medifast reported robust financial results for Q4 and FY 2021, with a 42.6% increase in quarterly revenue to $377.8 million and a 63.2% rise in annual revenue to $1.526 billion. Net income surged 21.5% in Q4 to $34.0 million and 59.5% for the year to $164.0 million. Diluted EPS reached $2.91 in Q4, up 23.3%, and $13.89 annually, an increase of 60.0%. However, gross profit margin fell 1.5% percentage points due to inflation impacts. The company expects FY 2022 revenue between $1.72 billion and $1.79 billion.